Gapping up
In reaction to earnings/guidance:
- YY +8%, AQUA +1.4%, WMT +0.9%, GDS +0.7%
Other news:
- LXRX +45.7% (reports SOLOIST and SCORED Phase 3 studies achieved their primary endpoints; Published in The New England Journal of Medicine)
- TSLA +13% (to join S&P 500)
- NEPT +10.5% (received over $100 mln in purchase orders)
- PGRE +8.6% (rejected unsolicited Bow Street acquisition proposal)
- SQNS +7.2% (filed for offerings)
- AXTI +5.9% (initiated process toward IPO for Tongmei subsidiary in China)
- RDHL +3.9% (second COVID-19 Candidate, RHB-107, cleared by FDA for Phase 2/3 study in symptomatic COVID-19 disease)
- KRMD +3.8% (authorized $10 mln stock repurchase program)
- COST +2.1% (declared $10/share special cash dividend)
- BMY +1.9% (provided regulatory update for liso-cel BLA)
- VRCA +1.6% (announces receipt of final FDA minutes following type A meeting regarding resubmission of the NDA for VP-102 in molluscum)
- AVRO +1.1% (new positive clinical data and preclinical data, as well as expanded leading lysosomal disorder gene therapy pipeline)